[go: up one dir, main page]

WO2006000158A8 - The use of laetispicine for manufacture of pharmaceutical composition - Google Patents

The use of laetispicine for manufacture of pharmaceutical composition

Info

Publication number
WO2006000158A8
WO2006000158A8 PCT/CN2005/000912 CN2005000912W WO2006000158A8 WO 2006000158 A8 WO2006000158 A8 WO 2006000158A8 CN 2005000912 W CN2005000912 W CN 2005000912W WO 2006000158 A8 WO2006000158 A8 WO 2006000158A8
Authority
WO
WIPO (PCT)
Prior art keywords
laetispicine
reuptake
pharmaceutical composition
monoamine neurotransmitter
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2005/000912
Other languages
French (fr)
Chinese (zh)
Other versions
WO2006000158A1 (en
Inventor
Sheng-Li Pan
Fu-Gang Qian
Jun Wang
Feng-Yan Sun
Jing Xie
Yi-Ci Shao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fudan University
Original Assignee
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fudan University filed Critical Fudan University
Publication of WO2006000158A1 publication Critical patent/WO2006000158A1/en
Publication of WO2006000158A8 publication Critical patent/WO2006000158A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention discloses the use of laetispicine for manufacture of pharmaceutical composition for certain diseases caused by central nerves system monoamine neurotransmitter reuptake disorder. The isotope labeling central nerves system monoamine neurotransmitter reuptake test certifies the inhibiting activity of laetispicine to the reuptake of 5-HT, NE AND DA by rats’ synaptosomes. The present laetispicine can be used as raw material to prepare pharmaceutical composition which can inhibit the reuptake of central nerves system monoamine neurotransmitter, in order to treat the related diseases caused by reuptake of central nervessystem monoamine neurotransmitter.
PCT/CN2005/000912 2004-06-25 2005-06-24 The use of laetispicine for manufacture of pharmaceutical composition Ceased WO2006000158A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2004100254930A CN1332656C (en) 2004-06-25 2004-06-25 Application of compound laetispicine in the process for preparing pharmaceutical composition
CN200410025493.0 2004-06-25

Publications (2)

Publication Number Publication Date
WO2006000158A1 WO2006000158A1 (en) 2006-01-05
WO2006000158A8 true WO2006000158A8 (en) 2006-02-09

Family

ID=34663697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2005/000912 Ceased WO2006000158A1 (en) 2004-06-25 2005-06-24 The use of laetispicine for manufacture of pharmaceutical composition

Country Status (2)

Country Link
CN (1) CN1332656C (en)
WO (1) WO2006000158A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101798297B (en) * 2009-02-11 2013-02-27 中国科学院上海药物研究所 The Chemical Synthesis Method of Ecketin
CN102240281B (en) * 2010-05-12 2014-05-14 天士力制药集团股份有限公司 Application of 5'-methoxy-3',4'-methylenedioxy cinnamic acid isobutyl amide in preparing antidepressant medicaments
CN102775394B (en) * 2011-05-12 2016-03-09 天士力制药集团股份有限公司 A kind of amides and its preparation method and application
CN104513172B (en) * 2013-09-30 2018-02-02 天士力医药集团股份有限公司 Acid amides alkaloid, preparation method and its medicinal usage containing trifluoromethyl
CN104940821A (en) * 2015-06-28 2015-09-30 李先强 Traditional Chinese medicine for treating split vision phobia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1389462A (en) * 2002-07-12 2003-01-08 复旦大学 Grandifoliate burchellin and its homologue and application in preparing composite medicine

Also Published As

Publication number Publication date
CN1593399A (en) 2005-03-16
CN1332656C (en) 2007-08-22
WO2006000158A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
MX337933B (en) Novel compositions for preventing and/or treating lysosomal storage disorders.
WO2007081542A3 (en) Tetralone-based monoamine reuptake inhibitors
WO2010078421A8 (en) Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
TW200740799A (en) Alpha2C adrenoreceptor agonists
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2008137923A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
TW200732296A (en) Novel compounds
MX2009000285A (en) Substituted piperidines that increase p53 activity and the uses thereof.
MY156822A (en) Indole derivatives as s1p1 receptor agonists
MX340807B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system.
TW200612892A (en) Novel compounds
IN2012DN02763A (en)
MX2009006345A (en) Compounds useful as protein kinase inhibitors.
MX2009006339A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity.
WO2006009836A3 (en) Tdf-related compounds and analogs thereof
TW200745003A (en) Novel compounds
WO2007022225A3 (en) Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
WO2010078369A3 (en) Pyrimidinediamine kinase inhibitors
WO2008144061A3 (en) Novel combinations comprising a phosphodiesterase-5 inhibitor and their use
TW200630336A (en) Novel compounds
TW200621690A (en) Novel compounds
WO2009037542A3 (en) Spirocyclic compounds as stearoyl coa desaturase inhibitors
MX2010009147A (en) Pyrrolidinyl derivatives and uses thereof.
MX2008012208A (en) Methods for treating cognitive and other disorders.
WO2009156680A3 (en) Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: PUBLISHED FIGURE REPLACED BY CORRECT FIGURE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase